IP Library › Granted Patent US 9,410,163
Granted Patent B2
US 9,410,163 · App. 14/571,515 · Granted Aug 9, 2016

Promoter-regulated differentiation-dependent self-deleting cassette

Inventors: David Frendewey (New York, NY); Guochun Gong (Elmsford, NY); Ka-Man Venus Lai (Tarrytown, NY); David M. Valenzuela (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12N15/8509A01K67/0275C12N9/1241C12N15/85C12N15/873C12N15/907A01K2217/07A01K2217/206A01K2227/105C12N2800/22C12N2800/30C12N2840/102
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,410,163
App. No.
14/571,515
Granted
Aug 9, 2016
Kind
B2
Abstract

Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3′-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.

Claims (17)

1. A targeting construct, comprising: first and second targeting arms flanking a cassette, wherein the cassette is flanked by first and second recombinase recognition sites oriented to direct an excision, and comprises

a) a nucleic acid sequence encoding a selectable marker; and

b) a first promoter operably linked to a recombinase gene,

wherein the recombinase gene encodes a recombinase that recognizes the first and the second recombinase recognition sites,

wherein the first promoter is the Blimp1 promoter SEQ ID NO:2 or the Blimp1 promoter SEQ ID NO:3,

wherein the first promoter drives expression of the recombinase gene in differentiated cells and does not drive expression of the recombinase gene in undifferentiated cells.

2. The targeting construct of claim 1 , further comprising a reporter gene between the first targeting arm and the first recombinase recognition site.

3. The targeting construct of claim 1 , wherein the first and the second recombinase recognition sites are lox sites, and the recombinase gene encodes a Cre recombinase.

4. The targeting construct of claim 1 , further comprising a second promoter, wherein the second promoter is operably linked to the nucleic acid sequence encoding the selectable marker.

5. The targeting construct of claim 1 , wherein the first promoter is the Blimp1 promoter SEQ ID NO:2.

6. The targeting construct of claim 1 , wherein the first promoter is the Blimp1 promoter SEQ ID NO:3.

7. A mouse embryonic stem (ES) cell comprising the targeting construct of claim 1 .

8. The mouse ES cell of claim 7 , wherein the targeting construct further comprises a reporter gene between the first targeting arm and the first recombinase recognition site.

9. The mouse ES cell of claim 7 , wherein the first and the second recombinase recognition sites are lox sites, and the recombinase gene encodes a Cre recombinase.

10. The mouse ES cell of claim 7 , wherein the targeting construct further comprises a second promoter, wherein the second promoter is operably linked to the nucleic acid sequence encoding the selectable marker.

11. The mouse ES cell of claim 7 , wherein the first promoter is the Blimp1promoter SEQ ID NO:2.

12. The mouse ES cell of claim 7 , wherein the first promoter is the Blimp1 promoter SEQ ID NO:3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2015
From: FRENDEWEY, DAVID; GONG, GUOCHUN; LAI, KA-MAN VENUS; VALENZUELA, DAVID M.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 034943/0512 →
Continuity (4)
Continuation 13934829 · Jul 3, 2013
Division 12856163 · Aug 13, 2010
Provisional Application 61233974 · Aug 14, 2009
Related Publication 20150099296A1 · Apr 9, 2015